Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Newave Pharmaceutical presents quinuclidinone analogues

Sep. 2, 2021

Cytokinetics synthesizes new Nampt activators

Sep. 2, 2021

All is loss for P53 mutations, study argues

Sep. 1, 2021

ErSO induces regression of human breast tumors in vivo

Sep. 1, 2021

Merck & Co. structure-based design efforts lead to new nucleoside PRMT5 inhibitors

Sep. 1, 2021

Japanese researchers synthesize new PROTACs for cancer

Sep. 1, 2021

Fileclo Sp zoo discloses new compounds for cancer

Sep. 1, 2021

Novel oxidative-phosphorylation inhibitors with promising antitumor activity in vivo

Sep. 1, 2021

New class of Mcl-1 inhibitors developed at Janssen for treating myeloma

Aug. 31, 2021

Low-dose targeted radionuclide therapy using [90Y]NM-600 promotes response to ICIs

Aug. 31, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.